Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

339
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
339
Physical Assessment of the Respiratory Tract II: Inspection01:27

Physical Assessment of the Respiratory Tract II: Inspection

945
Physical assessment of the respiratory tract through inspection is a crucial step in understanding the patient's respiratory health. It provides insights into the functioning of the respiratory system, the musculoskeletal structure, and even the patient's nutritional status. This comprehensive approach involves observing several vital aspects: chest configuration, breathing patterns, respiratory rates, skin color, and use of accessory muscles.
Chest Configuration
The chest configuration...
945
Physical Assessment of the Respiratory Tract II: Palpation01:24

Physical Assessment of the Respiratory Tract II: Palpation

2.0K
Physical assessment of the respiratory tract is critical in identifying potential health issues. One key component of this assessment is palpation, a technique healthcare providers use to assess the body for abnormalities. This content explores the method of palpation in evaluating the respiratory tract, focusing on thoracic palpation and tactile fremitus.
Thoracic Palpation
Thoracic palpation detects tenderness, masses, lesions, respiratory excursions, and vocal fremitus. The nurse assesses...
2.0K
Assessment of the Gastrointestinal System I: Subjective Data01:17

Assessment of the Gastrointestinal System I: Subjective Data

690
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
690
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

927
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
927
Physical Assessment of the Respiratory Tract I: Health History01:28

Physical Assessment of the Respiratory Tract I: Health History

937
Physical assessment of the respiratory tract is critical to patient care. It allows healthcare professionals to identify and manage various respiratory conditions. The process involves a combination of subjective and objective data collection.
Subjective Data
Subjective data provides vital information about the patient's health history and symptoms. This data is typically collected through interviews in which patients describe their experiences, symptoms, and concerns.
Health history and...
937

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

From candidate ranking to lead identification - Hydrophobic interaction chromatography, PAIA, and structure-based calculations for hydrophobicity determination during developability assessment of mAbs and a mAb-derived fusion protein.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Lyophilization of a viral vaccine: Strategies for surrogate use in analytical characterization of cake properties and considerations on virus infectivity.

Journal of pharmaceutical sciences·2026
Same author

Optimizing LOD/LOQ and sample consumption during analytical ultracentrifugation to characterize AAV gene therapy vectors.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Single Ni Atoms Drive Carboxyl Deprotonation in Metal-Organic Chains.

ACS nano·2026
Same author

Drug Product Development of Lipid Nanoparticle-Based mRNA Therapeutics and Vaccines.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same author

Evaluation of dimethyl sulfoxide-free formulations for cryopreservation of human T cells.

Journal of pharmaceutical sciences·2026

相关实验视频

Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

一个新的in silico平台,将数据驱动和基于物理的模型结合起来,用于评估蛋白质配方的可开发性.

Andrea Arsiccio1, Kristian Le Vay1, Andre Sao Pedro1

  • 1Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.

Journal of pharmaceutical sciences
|February 10, 2026
PubMed
概括

这项研究引入了一种新的计算平台,该平台只使用蛋白质序列来预测治疗性蛋白质稳定性和配方需求. 这种方法可以通过早期风险评估来减少昂贵的药物开发失败.

关键词:
生物制药特征的表征在模型建模.机器学习是机器学习.分子动力学分子动力学蛋白质蛋白质是一种蛋白质.蛋白质配方 (s) 蛋白质配方

更多相关视频

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

4.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.4K

相关实验视频

Last Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

4.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.4K

科学领域:

  • 生物制药开发 生物制药开发
  • 计算化学的计算化学
  • 蛋白质工程是指蛋白质工程.

背景情况:

  • 治疗性蛋白质的开发涉及大量投资,并面临高失败率.
  • 失败通常源于分子不稳定性和配方挑战,特别是在早期的发展阶段.
  • 有限的早期药物物质需要使用计算建模等替代评估方法.

研究的目的:

  • 介绍一个新的in silico平台,用于评估治疗性蛋白质配方的开发能力.
  • 减少与昂贵的药物开发失败相关的财务和时间风险.
  • 提供一种只需要蛋白质初级序列的方法,绕过了对物理材料的需求.

主要方法:

  • 开发一个新的in silico平台,集成数据驱动和基于物理的模型.
  • 利用计算技术,包括结构预测,生物信息学,机器学习和分子动力学.
  • 平台输入是治疗蛋白质的主要氨基酸序列.

主要成果:

  • 该平台识别了蛋白质负债和边缘性质.
  • 它评估了适用于高度配方的适用性和幕配方条件对自我相互作用的影响.
  • 该系统建议治疗性蛋白质的最佳配方走廊.

结论:

  • 开发的in silico平台为早期评估蛋白质药物候选人提供了强大的工具.
  • 它可以通过预测没有物理材料的配方开发能力来降低风险.
  • 案例研究证明了平台在现实场景中的适用性和实验验证.